The past decade has seen little progress in anticancer drugs for GC, leading to limited survival improvements lagging those in other malignancies.[51] At present, trastuzumab is the only effective targeted therapeutic drug for GC in clinical practice and can improve the prognosis of HER2‐positive GC patients.[52] However, only 10%–20% of GC cases show HER2 overexpression or amplification.[53] Thus, there is an urgent need to explore novel therapeutic targets for GC. The gene discussed is ERBB2; the disease is gastric cancer.